• MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

This Week on NeurologyLive® — February 28, 2022

Here's what is coming soon to NeurologyLive®.

Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive®, there are a number of hot topics that we will be posting on the website. As always, our weekly coverage extends beyond just these topics, so make sure to check out the rest of the site!

Click through the slides below to see what you can expect from our team this week:

slideshow image

Monday, February 28 is Rare Disease Day! The NeurologyLive® team has compiled a wide slate of coverage, including a feature offering updates and links to recent news for 10 rare neurological diseases. Additionally, the team’s coverage will include a dual Q&A on the importance of awareness days such as Rare Disease Day for patients with LGS with Steven Wolf, MD, and Patricia McGoldrick, NP, and a roundup of recent interviews with:

  • Tahseen Mozaffar, MD, FAAN, on AT845’s potential in Pompe disease
  • James F. Howard, MD, FAAN, on the recent approval of efgartigimod in gMG
  • Sabrina Paganoni, MD, on AMX0035’s potential in ALS
  • Darcy Kruger, MD, PhD, on preventing tuberous sclerosis complex
  • Veronica Hood, PhD, MS, on vaccinations and Dravet syndrome
slideshow image

Click the image to view more, or click the arrows to see the next slide.

The annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum took place last week, Feb 24-26. The NeurologyLive® team was on-site providing coverage straight from the conference floor, including in-depth conversations with experts and opinion leaders, as well as the latest on data readouts and sessions from the forum. Our coverage will continue into this week, so keep checking back for more!

To catch up on the coverage of ACTRIMS, click here.

slideshow image

Click the image to view more, or click the arrows to see the next slide.

The latest in our NeuroVoices series, dedicated to conversations with leaders in the neurology community, goes live on Wednesday, March 2. This week, it will feature a conversation with Matthew Schindler, MD, PhD, assistant professor of neurology, Pennsylvania Hospital, University of Pennsylvania, on the early prediction of chronic active lesion evolution from newly developing MS lesions using 7T MRI

To check out the prior NeuroVoices conversations, click here.

slideshow image

IN CASE YOU MISSED IT: The 58th episode of the NeurologyLive® Mind Moments™ podcast premiered on Friday, February 25! The show features an exclusive conversation with Konstantin Karmazin, MD, chief medical officer, Prime PD, who shared his insight into the digital wellness studio and its potential to improve care for patients with Parkinson disease and their physicians.

To listen and subscribe on your favorite podcast player, click here.

slideshow image

Click the image to view more, or click the arrows to see the next slide.

The MJH Life Sciences Medical World News streaming channel is on our midseason break for the next week of Season 5. But, it is still always streaming 24/7, so make sure to check out the channel for new episodes, and catch up on-demand with your favorites before the new episodes go live—and now you can catch up on all new content from season 5!

NeurologyLive® contributes regularly to all of our show offerings, so there is plenty of specialty-focused and outside area conversations, as well as more lighthearted content for you to view.

To catch up and check out what's on the Medical World News channel now, or check out hundreds of episodes on-demand, click here.

slideshow image

IN CASE YOU MISSED IT: The NeurologyLive® February 2022 issue went live last week! It includes feature articles by Adolfo Ramirez-Zamora, MD; Daniel Ackerman, MD, FAAN; and Crystal M. Proud, MD, and was led by guest editor-in-chief John Brandsema, MD. The issue covers topics in Parkinson disease, stroke, neuromuscular disorders, epilepsy, and much more—with a cover story on the ongoing shortage of neurologists.

To catch up on prior issues, click here.

slideshow image

Click the image to view more, or click the arrows to see the next slide.

IN CASE YOU MISSED IT: According to the National Institutes of Health’s clinical trials registry, more than 400 clinical trials of therapies designed to treat neurologic diseases are actively ongoing across phases 1 through 3 . Of those, more than 200 are in phase 3 development. Notably, many investigational therapies are addressing diseases with a high unmet clinical need, with either no currently available disease-modifying therapies or very limited options.

With so much activity in the clinical development pipeline, keeping up with the latest findings can sometimes be difficult. Here are 5 critical trials with expected data readouts in 2022 that NeurologyLive® will have its eye on.

PreviousNext


—————————————————